T prolymphocytic leukemia (T-PLL) is an unusual disease characterized by high white cell counts, older age at presentation, splenomegaly and a very aggressive clinical course. We describe a 47-year-old male with refractory T-PLL who was treated with high-dose chemoradiotherapy and allogeneic bone marrow transplantation (BMT) from an HLA-matched sibling. The transplant was complicated by both acute and chronic graft-versus-host disease (GVHD). The patient achieved complete remission and remains in remission 3 years after the transplant.
T prolymphocytic leukemia is a rare hematologic malignancy characterized by markedly elevated blood levels of atypical prolymphocytoid cells with cell surface markers of post-thymic T cells. [1] [2] [3] Although responses are sometimes observed to agents such as 2Ј-deoxycoformycin 1,4 and 2-chlorodeoxyadenosine, 5 a relentlessly progressive course is the rule, with a median survival of only 7.5 months. We report a patient with T-PLL successfully treated with allo-geneic BMT.
Case report
A 47-year-old male presented with left foot pain. Physical examination was suggestive of gout in the left first metatarsal-phalangeal joint. Adenopathy was not noted. The spleen was surgically absent. Scattered purplish papular lesions were noted on the trunk. The white cell count was 420 ϫ 10 9 /l, the hematocrit was 28%, and the platelet count was 30 ϫ 10 9 /l. Ninety-three per cent of the white cells had a prolymphocytoid appearance, being medium-sized, fairly uniform lymphoid cells, with fairly dense chromatin, scant cytoplasm and tightly folded and lobulated nuclei with single prominent nucleoli. Flow cytometric analysis showed 
Ϫ , TdT Ϫ ; myeloid and B-lymphoid markers were negative). Cytogenetic analysis showed t(14;14)(q11;q32). A skin biopsy revealed infiltration of the epidermis and dermis with atypical lymphocytes, consistent with leukemic infiltration. The patient was treated with leukapheresis and initially with therapy for ALL (based on a clinical impression of ALL, before all pathologic analysis had been completed): vincristine, prednisolone, daunorubicin and cytosine arabinoside; the white cell count decreased to 120 ϫ 10 9 /l. With the diagnosis of T prolymphocytic leukemia established, the patient was treated sequentially with 2-chlorodeoxyadenosine (0.14 mg/kg i.v. over 2 h daily for 5 days for two courses), high-dose corticosteroids (methylprednisolone 1 g intravenously for 3 days), and 2Ј-deoxycoformycin (4 mg/m 2 weekly for three doses), none of which resulted in a fall in white cell count any lower than 30 ϫ 10 9 /l. He then received high-dose cyclosphosphamide 60 mg/kg once daily i.v. on days 1 and 2 (total dose 120 mg/kg) and total body irradiation 12 Gy in six fractions followed by allogeneic bone marrow transplantation from his HLA-matched sister (nucleated cell dose 1.79 ϫ 10 8 /kg). He received cyclosporine and corticosteroids for GVHD prophylaxis. Engraftment occurred and he developed grade II acute GVHD involving the skin; this came under control with increased doses of corticosteroids. His subsequent post-transplant course was complicated by the development of idiopathic interstitial pneumonitis at day 150 which completely responded to corticosteroids, and mild chronic GVHD involving the skin and oral mucosa, which responded to corticosteroids. Bone marrow examination with flow cytometric and cytogenetic analysis showed trilineage engraftment with no evidence of disease at day 65, 12 months post-BMT, and 24 months post-BMT; cytogenetics revealed XX chromosomes, consistent with engraftment. At 36 months post-BMT the patient is alive and well with normal blood counts, no evidence of disease, and mild chronic GVHD limited to the skin of the forearms.
Discussion
T-PLL mainly affects elderly patients and is marked by splenomegaly, lymphadenopathy, skin infiltration, and very high white cell counts (median 200 000/l).
1-3 Immuno-logic markers are positive for pan-T markers, generally with a post-thymic phenotype (65% are CD4 ϩ , CD8 Ϫ ; 13% are CD4 Ϫ , CD8 ϩ ), although some cases are positive for both CD4 and CD8 (21%). The most common cytogenetic abnormality is inv(14)(q11;q32), seen in 76% of patients. Responses have been observed in patients treated with alkylating agents, 1 radiotherapy, 1 splenectomy, 1 2Ј-deoxyformycin, 1,4 2-chlorodeoxyadenosine, 5 and fludarabine. 6 However, most patients do not respond, and in those who do the response is transient. Median survival is only 7.5 months and the disease is considered essentially incurable. Our patient achieved long-term disease-free survival after treatment with high-dose chemoradiotherapy and allogeneic bone marrow transplantation, which was complicated by the development of both acute and chronic GVHD. It is not possible to determine the relative roles of chemoradiotherapy and graft-versus-leukemia (GVL) in the eradication of this patient's leukemia. Although local radiotherapy has activity in T-PLL, resulting in responses in three of seven patients in one study, 1 it is unknown whether TBI has significant activity. A potential GVL effect was observed in a patient with residual B-PLL after allogeneic BMT who appeared to respond to withdrawal of immunosuppression and development of GVHD. 7 Thus, our case demonstrates the potential curability of T-PLL by allogeneic BMT. However, as the median age at diagnosis is 69 years, most patients will not be suitable for treatment with standard BMT. However, new approaches are under investigation for performing allogeneic BMT in older patients, either by delivering lower doses of radiation or chemotherapy, 8, 9 or by more effectively controlling GVHD. 10 If successful, these approaches may enable more patients with T-PLL to undergo allogeneic BMT.
